DAVAGNINO JUAN,KHA CATHERINE NGAN,KLOTZ ALAN VOSKAMP
申请号：
NZ60816411
公开号：
NZ608164A
申请日:
2011.09.22
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
Disclosed is the use of a bG-CSF-T133pAF-20K PEG, a citrate or succinate buffer, arginine, and optionally a counter ion for arginine in the manufacture of a medicament for treatment of a disorder modulated by bG-CSF, wherein the medicament is a stable aqueous formulation containing less than 0.001% of a surfactant. Also disclosed is a stable aqueous formulation comprising bG-CSF-T133pAF-20K PEG, a citrate or succinate buffer, arginine, and optionally a counter ion for arginine, wherein said formulation contains less than 0.001% of a surfactant.
